Head-To-Head Analysis: Peak Bio (PKBO) & Its Competitors

Peak Bio (NASDAQ:PKBO) is one of 281 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Peak Bio to related businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Peak Bio and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
Peak Bio Competitors	1576	4701	12275	236	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 57.28%. Given Peak Bio’s rivals higher probable upside, analysts plainly believe Peak Bio has less favorable growth aspects than its rivals.

Profitability

This table compares Peak Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
Peak Bio Competitors	-5,053.49%	-170.27%	-42.13%

Institutional & Insider Ownership

50.3% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Peak Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Peak Bio’s rivals have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.

Valuation and Earnings

This table compares Peak Bio and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Peak Bio	$370,000.00	-$12.83 million	-0.24
Peak Bio Competitors	$550.94 million	-$34.05 million	-21.48

Peak Bio’s rivals have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Peak Bio beats its rivals on 6 of the 10 factors compared.

Peak Bio Company Profile

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.